Chinese pharmaceutical companies are proving their place in the US generic drugs market, with a rising number of approvals for copycat medicines almost doubling in the past year.
New start-up companies are constantly commercialising new technologies and services. Genomics is ripe for investment right now.
FDA Commissioner, Scott Gottlieb has critiqued health insurers, as he homes in on the increasingly popular target of rebates in the drug pricing debate.
Novartis is preparing to make some big changes to its structure following the departure of its operations chief, and a desire to aim for big digital things.
A life sciences expert has warned that obtaining CRISPR IP rights is expected to become a lot more difficult in the near future.
FDNA has announced a Genomics Collaborative, with the aim of developing new precision medicine approaches that builds on partnerships already underway in the research community.
Google has announced a partnership with WuXi NextCODE, with the aim of enhancing its comprehensive genomics capabilities.
Roche has unveiled plans to place a cancer specialist at the centre of its Swiss-based research efforts in April after the scientist who led the unit for five years, John Reed resigned for personal reasons.
Scott Gottlieb, head of the Food and Drug Administration (FDA) has revealed that a “rigged payment scheme” between drug plans, insurers and pharmaceutical companies has blocked access to less-expensive versions of some of the most expensive drugs in the U.S.